Helsinki, 19 October 2021 – The pricing board has granted conditional reimbursement for Mysimba® in Finland from 1 November 2021 in the treatment of obesity in support of drug-free treatment options.
Conditional reimbursement is granted to adults for the treatment of obesity in support of non-medicated treatment options when the patient has a BMI of 40 kg/m2 or more, or a BMI of 35 kg/m2 and drug therapy for type 2 diabetes, dyslipidemia or hypertension at the start of drug therapy.
The right of reimbursement is granted for six months at the first time. The right to further reimburse may be granted at the first time if the weight has decreased by at least 5% of the starting weight after the treatment lasted 16 weeks. Subsequently, the right to further reimburse may be granted if the weight is still 5% lower than at baseline.
The reimbursement approval is an important milestone in Navamedics strategy in providing a complete treatment solution for obese help-seeking patients to change eating & lifestyle behaviour, leading to sustained weight loss – with the consequence of reduced out-of-pocket spend for the individual patient.
“We are pleased to announce that we have received approval for conditional reimbursement for Mysimba in Finland. Navamedic is looking forward to expanding the availability of this unique medicine to the Finnish population,” says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.
“I am pleased we have yet another tool for treating obese patients, because there is no “one size fits all” solution. I welcome the reimbursement approval as it gives better opportunities for people to access this treatment, if the criteria set by the authorities are fulfilled,” says Dr. André Heikius, Medical Director and Executive Manager of Finnish Association for Obesity Medicine.
According to the World Health Organization, around 13% of the world’s population suffer from obesity, defined as abnormal or excessive fat accumulation that presents a risk to health, with a Body Mass Index (BMI) above 30. Obesity is a contributing risk factor for diseases such as cardiovascular diseases, diabetes and some cancers. According to Navamedic’s estimates, around 900 000 people in Finland are obese.
For further information, please contact:
Krister Sagulin, Country Manager Finland, Navamedic
Mobile: +35 8 400 463 201
Navamedic ASA is a Nordic pharma company and reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com
Mysimba is intended for weight control in adults over 18 years with baseline body mass index (BMI) ≥ 30 kg/m2 (obese), or ≥ 27 kg/m2 — < 30 kg/m2 (overweight) with one or more concomitant diseases associated with overweight, such as type 2 diabetes, dyslipidemia, or hypertension in the balance of treatment.